Understanding immune responses to Klebsiella pneumoniae O-antigens
Official title: Immune recognition of Klebsiella pneumoniae O2v1 and O2v2 O-antigen subtypes
Funded at Washington University · NIH-10892859 · Data updated 2026-11-12
This study is looking at how our immune system reacts to different types of a germ called Klebsiella pneumoniae, which can cause serious infections, to see if knowing about one type can help protect us from another, and this could help in making better vaccines against tough-to-treat infections.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $194,375 |
| NIH project number | 5R21AI166090-02 |
| Project ID | NIH-10892859 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for Klebsiella pneumoniae infections, such as hospitalized patients or those with weakened immune systems.
✕Less likely to help
Patients who are not at risk for Klebsiella pneumoniae infections or those who do not have a compromised immune system may not benefit from this research.
What this research studies
This research investigates how the immune system recognizes different subtypes of the O-antigen from Klebsiella pneumoniae, a bacterium that can cause serious infections. By studying the immune responses elicited by the O2v1 and O2v2 subtypes, the research aims to determine how these variations affect bacterial fitness and the body's susceptibility to infections. The project will also explore whether exposure to one subtype can provide protection against the other, which is crucial for developing effective vaccines against antibiotic-resistant strains of this bacterium.
Why it matters
Potential benefit: If successful, this research could lead to the development of vaccines that effectively protect against Klebsiella pneumoniae infections, particularly those that are resistant to antibiotics.
How similar studies have gone: Previous research has shown promise in developing vaccines targeting Klebsiella pneumoniae, indicating that this approach has potential for success.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Rosen, David a. — Washington University
- Study coordinator: Rosen, David a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.